Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Trial data show benefits of combination therapy in early stage breast cancer
October 13th, 2005
The Breast Cancer International Research Group (BCIRG) and sanofi-aventis announced results from an interim efficacy analysis of a Phase 3 trial which shows two Taxotere-based chemotherapy regimens in combination with Herceptin, monoclonal antibody therapy, significantly improved disease-free survival in women with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The BCIRG 006 trial compared a standard treatment arm of 4 cycles of doxorubicin and cyclophosphamide followed by Taxotere for 6 cycles, (AC-T) to two Herceptin-containing regimens following initial surgery. One arm included the above regimen with 1 year of Herceptin (AC-TH)...
Source: Women's Health Weekly (2005-10-13)
|
